IS8164A - Hringtengdar amínafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær - Google Patents

Hringtengdar amínafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær

Info

Publication number
IS8164A
IS8164A IS8164A IS8164A IS8164A IS 8164 A IS8164 A IS 8164A IS 8164 A IS8164 A IS 8164A IS 8164 A IS8164 A IS 8164A IS 8164 A IS8164 A IS 8164A
Authority
IS
Iceland
Prior art keywords
producing
methods
pharmaceutical compositions
compositions containing
cyclic amine
Prior art date
Application number
IS8164A
Other languages
English (en)
Inventor
Alvaro Giuseppe
Arista Luca
Cardullo Francesca
D'adamo Lucilla
Feriani Aldo
Giovannini Riccardo
Seri Catia
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS8164A publication Critical patent/IS8164A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
IS8164A 2003-05-09 2005-12-01 Hringtengdar amínafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær IS8164A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0310724.0A GB0310724D0 (en) 2003-05-09 2003-05-09 Chemical compounds
PCT/EP2004/005005 WO2004099143A1 (en) 2003-05-09 2004-05-07 Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
IS8164A true IS8164A (is) 2005-12-01

Family

ID=9957781

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8164A IS8164A (is) 2003-05-09 2005-12-01 Hringtengdar amínafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær

Country Status (21)

Country Link
US (2) US20070073061A1 (is)
EP (1) EP1622871A1 (is)
JP (1) JP4684221B2 (is)
KR (1) KR20060009313A (is)
CN (1) CN100534983C (is)
AR (1) AR044269A1 (is)
AU (1) AU2004235967B2 (is)
BR (1) BRPI0410154A (is)
CA (1) CA2524894A1 (is)
EG (1) EG24668A (is)
GB (1) GB0310724D0 (is)
IS (1) IS8164A (is)
MA (1) MA27795A1 (is)
MX (1) MXPA05012096A (is)
MY (1) MY140027A (is)
NO (1) NO20055835L (is)
NZ (1) NZ543068A (is)
RU (1) RU2392270C2 (is)
TW (1) TWI332499B (is)
WO (1) WO2004099143A1 (is)
ZA (1) ZA200508339B (is)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412865D0 (en) 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
US7844037B2 (en) 2005-08-08 2010-11-30 Palm, Inc. Method and device for enabling message responses to incoming phone calls
EP2094692B1 (en) 2006-11-01 2012-11-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1 and/or nf-kappab activity and use thereof
CA2735768A1 (en) * 2008-09-01 2010-03-04 Neurosearch A/S Novel piperidine-4-acetamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
DK2729147T3 (en) 2011-07-04 2017-12-18 Irbm - Science Park S P A NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF CORNOVA
CN106187999A (zh) * 2015-05-04 2016-12-07 复旦大学 取代哌啶类化合物及其制备方法和用途
EP4313302A1 (en) * 2021-03-23 2024-02-07 Bioage Labs, Inc. Inhibitors of nlrp3 inflammasome
US11787805B2 (en) 2022-01-28 2023-10-17 BioAge Labs, Inc. N-oxide inhibitors of NLRP3 inflammasome

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US309720A (en) * 1884-12-23 William p
NL262366A (is) * 1960-03-14
GB1356117A (en) * 1970-12-16 1974-06-12 Searle & Co 1-3-cyano-3,3-diphenylpropyl-4-phenylpiperidine-4-carboxylic acid derivatives
US5635510A (en) * 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
DE19603767A1 (de) * 1996-02-02 1997-08-07 Hoechst Ag Pyrrolidinpropionsäurederivate mit bradykinin-antagonistischer Wirkung
WO1999025685A1 (en) * 1997-11-18 1999-05-27 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6020347A (en) * 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6423519B1 (en) * 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
EP1377293B1 (en) * 2001-04-12 2010-03-10 Pharmacopeia, LLC Aryl and biaryl piperidines used as mch antagonists
ATE446286T1 (de) * 2001-11-26 2009-11-15 Schering Corp Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US20060128752A1 (en) * 2002-07-03 2006-06-15 Giuseppe Alvaro Chemical compounds

Also Published As

Publication number Publication date
TW200510309A (en) 2005-03-16
ZA200508339B (en) 2006-10-25
MXPA05012096A (es) 2006-02-08
AU2004235967A1 (en) 2004-11-18
KR20060009313A (ko) 2006-01-31
NO20055835L (no) 2006-02-07
EG24668A (en) 2010-04-11
AU2004235967B2 (en) 2008-10-23
JP4684221B2 (ja) 2011-05-18
US20070073061A1 (en) 2007-03-29
RU2392270C2 (ru) 2010-06-20
NZ543068A (en) 2009-07-31
BRPI0410154A (pt) 2006-05-16
TWI332499B (en) 2010-11-01
CN100534983C (zh) 2009-09-02
GB0310724D0 (en) 2003-06-11
EP1622871A1 (en) 2006-02-08
JP2006525975A (ja) 2006-11-16
NO20055835D0 (no) 2005-12-08
AR044269A1 (es) 2005-09-07
MA27795A1 (fr) 2006-03-01
CA2524894A1 (en) 2004-11-18
US20090192194A1 (en) 2009-07-30
CN1819995A (zh) 2006-08-16
MY140027A (en) 2009-11-30
RU2005138315A (ru) 2007-06-20
WO2004099143A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
IS8024A (is) Adamantanafleiður, aðferðir til að framleiða þær og lyfjablanda sem inniheldur þær
IS7543A (is) Bensóþíadíasepínafleiður, aðferðir til framleiðslu þeirra og lyfjablöndur sem innihalda þær
IS7261A (is) N-adamantýlmetýlafleiður og milliefni sem lyfjablöndur og aðferðir til að framleiða þær
IS7552A (is) Bensótengdar heteróarýl amíð afleiður af þíenópýridíni, gagnlegar sem meðferðarmiðlar, lyfjasamsetningar sem innihalda þær og aðferðir við notkun þeirra
NO20054006D0 (no) Cykliske ureaderivater, fremstillingsfremgangsmate derav og farmasoytisk anvendelse av samme som kinaseinhibitorer
IS8164A (is) Hringtengdar amínafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær
DK1720544T3 (da) Nye azabicykliske derivater, fremstillingsmetode hertil og farmaceutiske sammensætninger indeholdende disse
DE60307794D1 (de) Verfahren zum Verpacken, Packmittel und dessen Herstellungsverfahren
DK1913001T3 (da) (r)-n-methylnaltrexon, fremgangsmåder til syntese og farmaceutisk anvendelse heraf
NO20050741D0 (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
PL380851A1 (pl) Nowe pochodne pirydynowe, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne
BR0308452A (pt) composições farmacêuticas e métodos de preparação de composição farmacêutica
IS7226A (is) Fjölbrigða form af rimonabant, framleiðsluaðferð og lyfjasamsetningar sem innihalda það
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
IS8069A (is) Aðferðir og lyfjasamsetningar til að ná áreiðanlega ásættanlegum testósterónstyrk
ATE471931T1 (de) Verbindungen, zusammensetzungen und verfahren
IS2979B (is) Aðferð til að framleiða N-útskipt 2-sýanópýrrólídín
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
NO20052683D0 (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
EP1680109A4 (en) AMIDE DERIVATIVES AS ION CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE DERIVATIVES
NO20053809D0 (no) Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
NO20065279L (no) Sproytepose, emne for fremstilling av sproytepose, og fremgangsmate for fremstilling av sproytepose
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
DK1518827T3 (da) Krystalliseret IM-12-faststof og fremgangsmåde til fremstilling heraf